Tag: KDC-MN-1541

  • Capromorelin

    Orally active pyrazolinone-piperidine dipeptide growth hormone secretagogue receptor type 1a (GHS-R1a) agonist

    A non-peptide ghrelin receptor agonist developed at Pfizer as a peptidomimetic growth hormone secretagogue for age-related functional decline, subsequently approved in veterinary medicine for appetite stimulation in dogs and weight management in cats with chronic kidney disease.

    Abstract

    Capromorelin (CP-424,391) is an orally active, non-peptide agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) belonging to the pyrazolinone-piperidine dipeptide structural class. The compound was discovered at Pfizer Global Research and Development through systematic structure-activity optimization of peptidomimetic scaffolds and was selected as a clinical development candidate on the basis of high receptor affinity (Ki = 7 nM at human GHS-R1a), potent functional activity (EC50 = 3 nM in rat pituicyte growth hormone release assay), oral bioavailability, and robust in vivo growth hormone secretion in rodent and canine models [1, 2]. Capromorelin mimics the endogenous acylated peptide hormone ghrelin by binding the GHS-R1a receptor on somatotroph cells of the anterior pituitary gland and on hypothalamic neurons, activating Gq/11-coupled phospholipase C signaling, intracellular calcium mobilization, and consequent pulsatile growth hormone release through a pathway mechanistically distinct from and synergistic with the growth hormone releasing hormone (GHRH) receptor pathway. Secondary pharmacological activities include appetite stimulation through hypothalamic orexigenic circuits, transient elevation of circulating cortisol and prolactin, and sustained elevation of insulin-like growth factor 1 (IGF-1) on chronic dosing. Human clinical development was subsequently discontinued; the compound did not advance to Phase III registration trials for age-related sarcopenia or functional decline. These veterinary approvals represent the only registered therapeutic applications of capromorelin as of the most recent monograph revision. The compound is the first and only FDA-approved ghrelin receptor agonist for appetite stimulation in companion animals and demonstrates the translational validity of the GHS-R1a mechanism for orexigenic and anabolic applications. Pharmacokinetics in dogs are characterized by rapid oral absorption (Tmax approximately 0.83 hours), moderate oral bioavailability (44 percent), hepatic metabolism predominantly through CYP3A4 and CYP3A5 mediated N-dealkylation and O-debenzylation, and a short terminal elimination half-life (approximately 1.2 hours in dogs, 2.4 hours in rats) [2, 15, 16]. The compound is well tolerated at studied doses; the principal adverse events across species are transient hypersalivation, mild emesis, loose stools, and transient increases in serum cortisol and glucose concentrations that normalize within hours of dosing. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.